Advice
Following a full submission
Ciclesonide (Alvesco) is accepted for restricted use within NHS Scotland for treatment to control persistent asthma in adolescents (aged at least 12 years and <18 years)
It is restricted to asthma patients who require once-daily administration of an inhaled corticosteroid and whose treatment is at step 2 or step 3 of the British Guideline on the Management of Asthma. Alternative inhaled steroids are available at lower cost.
Download detailed advice44KB (PDF)
Medicine details
- Medicine name:
- Ciclesonide (Alvesco®)
- SMC ID:
- 249/06
- Indication:
- Persistent asthma in adolescents aged 12 years and over
- Pharmaceutical company
- Altana Pharma Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 12 June 2006